Table 1.

Baseline characteristics and demographics for subjects included in the study.

Subject ID	Age	Gender	Date of diagnosis	Current treatment	Prior treatment	IgG mg/dL	Absolute lymphocyte Count (K/mm3)	B-cells (CD19+) %	Naïve B-cells (IgD+CD27−) %	Memory B-cells (IgD−CD27+) %	B1 B-cells (CD5+CD19+) %
						(768–1632)	(1.00–4.80)	(4–17)	(50–80)	(5–21)	(<6)
1	60's	F	17/02/2014	None	None	834	21.09	76	0.092	59.1	76.18
2	80's	F	02/01/2014	Ibrutinib (2017)	Obinutuzumab × 6 cycles (completed 2015)	510	5.93	61	11.37	0.45	59.96

Note. Normal ranges for each of the B-cell subsets are in parenthesis under each B-cell type.